FDA Approves Moderna's Next-Generation COVID-19 Vaccine for Adults 65+
The FDA has approved Moderna's new lower-dose COVID-19 vaccine, mNexspike, for use in adults 65+ and at-risk individuals aged 12-64, providing an additional tool for COVID-19 protection, especially for high-risk groups, based on a study showing it is safe and effective.